¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"time factors"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£, Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£
  • interaural time difference
    ¾ç±Í°£µµ´Þ½Ã°£Â÷
  • intraatrial conduction time
    ½É¹æ³»Àüµµ½Ã°£
  • kaolin clotting time
    Ä«¿Ã¸°ÀÀ°í½Ã°£
  • latent time
    Àẹ½Ã°£
  • lead time
    Á¶±â¹ß°ß±â°£
  • maximum phonation time
    ÃÖÀå¹ß¼ºÁö¼Ó½Ã°£
  • mean tidal time
    Æò±Õ¼øÈ¯½Ã°£
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • polymerizing time
    ÁßÇսð£
  • potential doubling time
    ÀáÀç¹è°¡½Ã°£
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • partial thromboplastin time
    ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • time-dose-fractionation formula
    ½Ã°£¼±·®ºÐÇÒ°ø½Ä
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • inertia time
    Ÿ¼º½Ã°£
  • influx time
    À¯ÀԽð£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
  • inspiratory triggering response time
    µé¼ûÀ¯¹ß¹ÝÀÀ½Ã°£
  • intercostal real-time scanning
    °¥ºñ»çÀ̽ǽ𣽺ij´×, ´Á°£½Ç½Ã°£½ºÄ³´×
  • intraretinal transit time
    ¸Á¸·³»ÀÌÇà½Ã°£
  • inversion time
    ¿ªÀü½Ã°£
  • ischemic time
    ÇãÇ÷½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • generation time =doubling t.
    ¼¼´ë½Ã°£(á¦ÓÛãÁÊà), ¹èÀ§½Ã°£(ÛÃêÈãÁÊà), ¼¼´ë±â(á¦ÓÛÑ¢).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • hardening time
    °æÈ­½Ã°£(¡­ãÁÊà).
  • inertia time
    Ÿ¼º½Ã°£(öçàõãÁÊà)
  • influx time
    À¯ÀԽð£(êüìýãÁÊà).
  • inspiratory pause time
    Èí±âÈÄÈÞÁö½Ã°£.
  • inspiratory phase time
    Èí±â»ó½Ã°£.
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • persistence time
    Áö¼Ó½Ã°£(ò¥áÙãÁÊà).
  • phonation time
    ¹ß¼ºÁö¼Ó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • polymerizing time
    ±»´Â ½Ã°£ (ÁßÇÕ ½Ã°£)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cell cycle time
    ¼¼Æ÷ÁÖ±â½Ã°£
  • circulation time
    ¼øÈ¯ ½Ã°£(âàü»ãÁÊà)
  • clot retraction time
    Ç÷º´ÅðÃà½Ã°£(¡­ãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ëêͳãÁÊà)
  • clotting time
    ÀÀ°í½Ã°£(ËôË­Ëà˧) ÊÙÇ÷¾×ÀÇÊÙ.
  • clotting time of whole blood
    ÀüÇ÷ÀÀ°í½Ã°£(îïúìëêͳãÁÊà)
  • clotting time of whole blood
    [³»°ú,ÀÓº´]ÀüÇ÷ÀÀÇ÷½Ã°£(îïúìëêúìãÁÊà).
  • clotting time of whole blood
    [³»°ú,ÀÓº´]ÀüÇ÷ÀÀÇ÷½Ã°£(ËøÌ´ËôÌ´Ëà˧).
  • coagulation time
    ÀÀ°í½Ã°£(¡­ãÁÊà) ¡ìÇ÷¾×ÀÇ¡í.
  • corrected sinus node recovery time
    ±³Á¤ µ¿°áÀý ȸº¹½Ã°£.
  • correlation time
    »ó°ü ½Ã°£
  • data acquisition time
    ÀÚ·á ȹµæ ½Ã°£
  • death time, thermal
    ¿­»ç¸ê½Ã°£
  • delay time
    Áö¿¬ ½Ã°£
  • dextrinizing time
    ÀüºÐÀüÈ­½Ã°£(îþÝÏï®ûùãÁÊà).
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • repetition time [=TR]
    ¹Ýº¹½Ã°£
  • ring down time
    ¿©¿î½Ã°£
  • rise time
    »ó½Â½Ã°£
  • rising time
    »ó½Â½Ã°£
  • scan time
    ÁÖ»ç½Ã°£
  • spin lattice relaxation time (T1)
    ½ºÇɰÝÀÚÀ̿Ͻð£(T1)
  • spin spin relaxation time
    ½ºÇɽºÇÉÀ̿Ͻð£
  • T.G.C [=time gain compensation]
    ½Ã°£°ÔÀκ¸»ó
  • T1 relaxation time
    T1À̿Ͻð£
  • T2 (spin spin) relaxation time
    T2(½ºÇɽºÇÉ)À̿Ͻð£
  • T2 relaxation time
    T2À̿Ͻð£
  • temporal window(scan time)
    ÀϽÃÀû â
  • time compensation curve
    ½Ã°£º¸»ó°î¼±
  • time gain compensation [=T.G.C.]
    ½Ã°£°ÔÀκ¸»ó
  • time gain compenstaion curve
    ½Ã°£°ÔÀκ¸»ó°î¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
TR recovery time; rectal temperature; repetition time; residual tuberculin; terminal repeat; tetrazoliu...
TTI tension-time index; time-tension index; timepto-intubation; torque-time interval; transtracheal insu...
ANF Atrial Natriuretic Factors
ECF   1) Eosinophilic Chemotatic Factors
  2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾×
NCF Neutrophilic Chemotatic Factors
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HGF Hemopoietic growth factors
HBGF Heparin binding growth factors
IGFBPs Insulin-like growth factors and their binding proteins
IGF-II Insulin-like growth factors I and II
MRF Monoclonal rheumatoid factors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • relaxation time
    ÀÌ¿Ï ½Ã°£
  • retention time
    ÀÜ·ù ½Ã°£
  • setting time
    °æÈ­ ½Ã°£, ÀÀ°í ½Ã°£, ±»´Â ½Ã°£
    1. ºñÄÏ Ä§À» »ç¿ëÇÏ¿© ¿¬È­ °³½Ã¿¡¼­ ħÀÔ±íÀ̰¡ 1§® ÀÌÇϰ¡ µÉ ¶§±îÁöÀÇ ½Ã°£À» °æÈ­ ½Ã°£À̶ó ÇÑ´Ù. ¾ö¹ÐÈ÷ Ãʱ⠰æÈ­ ½Ã°£ÀÌ´Ù. 2. È¥ÇÕ ½ÃÀÛºÎÅÍ Àç·á°¡ ÃæºÐÇÏ¿© ÀÓ»óÀûÀ¸·Î À¯ÀǼºÀÌ ÀÖ´Â ¿µ±¸ º¯Çü ¾øÀÌ ÀλóÀ» ±¸°­ ³»¿¡¼­ Á¦°ÅÇÒ ¼ö Àִµ¥ ¼Ò¿äµÇ´Â ÃÖ¼ÒÇÑÀÇ ½Ã°£.
  • T2 relaxation time
    T2 ÀÌ¿Ï ½Ã°£
  • T2 spin spin relaxation time
    T2 ½ºÇÉ ½ºÇÉ ÀÌ¿Ï ½Ã°£
  • thermal camera time response
    ¿­ Ä«¸Þ¶ó ½Ã°£ ¹ÝÀÀ
  • time
    ½Ã°£, ¶§
    ¾î¶² ½Ã°¢°ú ½Ã°¢ÀÇ »çÀÌ.
  • time cycled ventilator
    ½Ã°£ ÁÖ±â È£Èí±â
  • time difference
    ½ÃÂ÷
  • time gain compensation
    ½Ã°£ °ÔÀÎ º¸»ó
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
  • time lag
    Áöü ½Ã°£
  • time of death
    »ç¸Á ½Ã°¢
  • time of flight
    È帧 ½Ã°£, À¯Ã¼ ¼Óµµ °­Á¶
  • time of flight phenomenon
    À¯Ã¼ ¼Óµµ °­Á¶ Çö»ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
haemolysin factors Plasmids controlling the synthesis of haemolysin by bacteria.
(12 Dec 1998)
precipitating factors Factors associated with the definitive onset of a disease, illness, accident, behavioural response, or course of action. Usually one factor is more important or more obviously recognizable than others, if several are involved, and one may often be regarded as "necessary". Examples include exposure to specific disease; amount or level of an infectious organism, drug, or noxious agent, etc.
(12 Dec 1998)
predisposing factors Attitudinal, personality, and related factors that motivate and guide an individual to take certain health actions.
(05 Mar 2000)
sex factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from sex characteristics, anatomical or physiological manifestations of sex, and from sex distribution, the number of males and females in given circumstances.
(12 Dec 1998)
socioeconomic factors Social and economic factors that characterise the individual or group within the social structure.
(12 Dec 1998)
steam conversion factors (approximations) 1 pound of steam = 1,000 Btu = .3 kW. 10,000 lbs/hr steam = 300 boiler horsepower.
(05 Dec 1998)
stem cell growth factors <growth factor> Compounds, usually proteins, that make stem cells grow faster.
(26 Mar 1998)
nerve growth factors Factors which enhance the growth potentialities of sensory and sympathetic nerve cells.
(12 Dec 1998)
debranching factors Enzyme's that bring about destruction of branches in glycogen; formerly considered to be one enzyme, now known to be a mixture of transferases (4-alpha-d-glucanotransferase) and hydrolases (amylo-1,6-glucosidase).
Synonym: debranching factors.
(05 Mar 2000)
suppressor factors, immunologic Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory.
(12 Dec 1998)
direct lytic factors most abundant proteins in cobra (naja of the elapids) venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contracture, interferes with neuromuscular and ganglionic transmission, depolarises nerve, muscle and blood cell membranes, thus causing haemolysis.
Synonym: cobramine a; cobramine b; cobra cytotoxin; gamma toxin; membrane-active polypeptide.
(12 Dec 1998)
immunologic and biological factors A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity.
(12 Dec 1998)
immunologic factors Biologically active substances whose activities affect or play a role in the functioning of the immune system.
(12 Dec 1998)
initiation factors The set of catalytic proteins required, in addition to mRNA and ribosomes, for protein synthesis to begin. In bacteria three distinct proteins have been identified: if 1 (8 kD), IF 2 (75 kD) and IF 3 (30 kD). at least 6-8 proteins have been identified in eukaryotes. IFs 1 and 2 enhance the binding of initiator tRNA to the initiation complex.
(18 Nov 1997)
insulin-like growth factors Peptides whose formation is stimulated by growth hormone. These peptides bring about peripheral tissue effects of that hormone and have high (about 70%) homology to human insulin.
Synonym: somatomedins.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • T-time
    ·ÎÄÏ ¹ß»ç ½Ã°£
  • Time Square
    New York ½ÃÀDZØÀå°¡
  • access time
    È£Ãâ½Ã°£(±â¾ï ÀåÄ¡¿¡ Á¤º¸¸¦ ±â·Ï,ÇØµ¶ÄÉ Çϱâ À§ÇÑ ½Ã°£);ÄÄÇ»ÅÍ¿ë¾î
  • apparent time
    (ÇØ½Ã°èµîÀÇ)žçÀÇ À§Ä¡·Î ÃøÁ¤Çϴ½ð£
  • atomic time clock
    ¿øÀÚ ¿¬´ë ½Ã°è
  • atonic time clock
    ¿øÀÚ¿¬´ë
  • bad time
    °ï°æ
  • church time
    ¿¹¹è ½Ã°£
  • close time
    =CLOSE SEASON
  • closing time
    ÆóÁ¡(Á¾¾÷)½Ã°£
  • common time
    º¸ÅëÀÇ ¹ÚÀÚ(ƯÈ÷ 4ºÐÀÇ 4¹ÚÀÚ)
  • cooling time
    =COOLING-OFF PERIOD
  • coordinated universal time
    ÇùÁ¤ ¼¼°è½Ã(UTC)
  • core time
    ÄÚ¾î ŸÀÓ;Çٽð£(ÀÚÀ¯±Ù¹«½Ã°£(flextime)¿¡¼­ ¹Ýµå½Ã ±Ù¹«ÇØ¾ß ÇÏ´Â ½Å°£´ë)
  • cycle time
    »çÀÌŬ ŸÀÓ(±â¾ï ÀåÄ¡ÀÇ Àд ¼Óµµ)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á